Rezolute (RZLT) AI Stock Analysis

• Market Cap: $238.29M
• Dividend Yield: N/A
• Average Volume (3M): 2.66M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: N/A
• EPS Growth: 26.65%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 95,697,685
• 10 Day Avg. Volume: 3,536,431
• 30 Day Avg. Volume: 2,661,481
• PEG Ratio: 0.17
• Price to Book (P/B): 2.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.91
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -15.11K
• Enterprise Value/Ebitda: -2.57
• 1Y Price Target: $4.00
• Price Target Upside: 60.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.76
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $2.50 ▲(0.40% Upside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is held down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn) and a bearish technical setup (price below major moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend, while the latest corporate update adds uncertainty after a Phase 3 miss despite some encouraging secondary observations and regulatory planning.

Positive Factors

Low leverage / strong balance sheet

Very low debt and sizable assets give Rezolute meaningful financial flexibility for a clinical-stage biopharma. Low leverage reduces refinancing pressure and supports continued R&D and regulatory engagement, improving the ability to fund trials or execute partnerships over the medium term.

Demonstrated clinical benefit in expanded access

Expanded access results showing 75% of severe tumor hyperinsulinism patients stopping IV/TPN indicate ersodetug can deliver meaningful clinical benefit in a high-need niche. Durable clinical signal in a refractory population supports targeted regulatory strategies and potential commercial value if confirmed.

Breakthrough Therapy designation and FDA engagement

Having Breakthrough Therapy designation and planned FDA discussions creates an expedited regulatory channel. This structural advantage can accelerate development, enable negotiation of adaptive or alternative endpoints, and increase the odds of an efficient regulatory path if clinical signals are clarified.

Negative Factors

Pre-revenue with widening net losses

Rezolute remains pre-commercial while net losses have widened substantially, meaning no product revenues exist to offset costs. Persistent losses erode equity over time and force reliance on external capital, which can dilute shareholders and limit strategic options if market conditions worsen.

Sustained heavy cash burn

Consistently negative operating and free cash flow signal the company cannot self-fund development and heighten runway risk. Ongoing cash consumption increases dependence on financing, which can delay programs, force prioritization of assets, or cause execution risk if capital markets tighten.

Phase 3 failure increases regulatory/development risk

A Phase 3 trial missing primary and key secondary endpoints is a fundamental development setback. It creates regulatory uncertainty, may require trial redesigns or additional studies, delays potential approval and commercialization, and raises the risk that clinical outcomes won't translate into a viable product.

Rezolute Business Overview & Revenue Model

Company Description

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Rezolute has not historically generated meaningful recurring revenue from product sales; its operations are primarily funded through external financing rather than commercial income. The company’s potential future revenue model would typically be driven by (1) product sales if a lead candidate receives regulatory approval and is commercialized, and/or (2) strategic collaborations such as licensing agreements that could include upfront payments, development and regulatory milestone payments, sales-based milestones, and royalties. Specific, current revenue streams, material product revenues, or definitive partnership economics are null.

Rezolute Financial Statement Overview

Summary

Financial profile is weak overall: the company remains pre-revenue with materially widening net losses (to about -$84.2M TTM) and deteriorating operating/free cash flow (about -$77.1M TTM). The balance sheet is a relative bright spot with very low leverage (debt-to-equity ~0.01) and sizable assets, but persistent losses imply ongoing funding/runway risk.

Income Statement

The income statement remains very weak, with zero revenue across annual periods and TTM (Trailing-Twelve-Months), indicating the business is still pre-commercial. Losses have widened materially versus prior years (net loss moving from about -$20.9M in 2021 to -$74.4M in 2025 annual and -$84.2M in TTM), reflecting a rising cost structure without offsetting sales. The main positive is that the company appears well-funded enough to sustain R&D spend in the near term, but profitability is not yet in sight based on the provided trajectory.

Balance Sheet

The balance sheet is a relative strength: leverage is very low (debt-to-equity ~0.01 in 2025 annual and ~0.01 in TTM), with debt of roughly $1–2M against equity of ~$128–162M. Total assets also remain sizable (~$139M in TTM). The key weakness is persistent, large losses driving deeply negative returns on equity (roughly -46% in 2025 annual and about -63% in TTM), which can pressure equity over time if cash burn continues.

Cash Flow

Cash flow quality is weak due to heavy ongoing burn: operating cash flow and free cash flow are consistently negative and have deteriorated over time (about -$20.4M in 2021 to -$69.1M in 2025 annual and -$77.1M in TTM). While the reported free cash flow growth in TTM is positive, it is coming off a very negative base and does not change the underlying picture of sustained cash consumption. The company’s cash generation does not currently support self-funding operations, increasing reliance on external financing.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-15.00K	0.00	0.00	0.00	0.00	-13.00K
EBITDA	-88.21M	-79.86M	-70.39M	-55.96M	-39.24M	-20.51M
Net Income	-84.23M	-74.41M	-68.46M	-51.79M	-41.06M	-20.90M
Balance Sheet
Total Assets	138.63M	175.49M	132.74M	123.72M	152.42M	42.61M
Cash, Cash Equivalents and Short-Term Investments	132.94M	167.86M	126.87M	101.90M	150.41M	41.05M
Total Debt	1.28M	1.61M	2.23M	2.48M	188.00K	14.42M
Total Liabilities	10.63M	13.36M	11.73M	7.55M	2.95M	16.51M
Stockholders Equity	128.00M	162.13M	121.00M	116.17M	149.47M	26.10M
Cash Flow
Free Cash Flow	-77.15M	-69.08M	-57.37M	-44.63M	-39.62M	-20.44M
Operating Cash Flow	-77.15M	-69.08M	-57.37M	-44.48M	-39.62M	-20.44M
Investing Cash Flow	-22.28M	-14.54M	48.70M	-101.46M	0.00	0.00
Financing Cash Flow	102.44M	107.33M	63.03M	11.57M	148.98M	51.53M

Rezolute Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RZLT, the sentiment is Negative. The current price of 2.49 is below the 20-day moving average (MA) of 3.01, below the 50-day MA of 3.09, and below the 200-day MA of 5.84, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 36.12 is Neutral, neither overbought nor oversold. The STOCH value of 13.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RZLT.

Rezolute Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GERN	57 Neutral	$935.20M	―	-34.23%	―	522.13%	62.68%
KOD	54 Neutral	$1.36B	-3.52	-246.19%	―	―	-12.93%
TSHA	53 Neutral	$1.26B	-16.13	-56.64%	―	-36.36%	-945.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABUS	48 Neutral	$815.45M	-28.12	-50.20%	―	116.64%	47.93%
RZLT	44 Neutral	$238.29M	-2.69	-64.81%	―	―	26.65%
XNCR	43 Neutral	$889.60M	-12.36	-14.58%	―	38.16%	48.43%

Rezolute Corporate Events

Rezolute Updates sunRIZE Phase 3 Trial and FDA Plans

On January 7, 2025, Rezolute reported detailed observations from its Phase 3 sunRIZE trial in congenital hyperinsulinism, noting that although the study did not meet its primary and key secondary endpoints for reducing hypoglycemia events and time in hypoglycemia, data showed clear pharmacologic activity of ersodetug and reductions from baseline that were confounded by a strong placebo effect and study design factors in an ambulatory glucose-monitoring setting. The company highlighted that all 59 patients who completed the controlled phase of sunRIZE chose to continue into the open-label extension and that many children there have discontinued all other therapies and remain on ersodetug monotherapy, while Rezolute prepares to discuss the full dataset and potential regulatory path with the FDA under its Breakthrough Therapy Designation in early 2026. Rezolute also released cumulative data from the first nine tumor hyperinsulinism patients treated with ersodetug in its expanded access program over the past two years, showing that 75% of those on IV dextrose or total parenteral nutrition were able to fully discontinue these infusions, evidence that supported redesign of the Phase 3 upLIFT tumor HI trial into a single-arm, open-label study using glucose infusion rate reduction as the primary endpoint and underscored the potential of ersodetug to address severe, refractory hypoglycemia in this population.

The most recent analyst rating on (RZLT) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Rezolute stock, see the RZLT Stock Forecast page.